Founded in 2016, Adelaide-based Splose offers physiotherapists, occupational therapists, speech pathologists and other allied health practitioners a single platform to manage appointments, onboarding, invoicing and compliance. The company has embedded AI tools such as transcription, automated note-taking, reporting and workflow automation, generating more than 200,000 AI outputs each month. Over 20,000 individual practitioners across Australia, New Zealand and the UK now use the software, with user numbers growing at more than 100% year-on-year and UK usage expanding 300% in the last 18 months. Popular AI features include AI Scribe, Ask AI, AI Blocks and an email assistant, which Splose claims let clinicians create notes four times faster than manual methods. Management emphasizes deep product integration and community-led development as its competitive moat against legacy practice-management systems. While profitability metrics were not disclosed, the company’s valuation is reported to be comfortably above $100 million. New capital will accelerate product development, deepen AI workflows, improve payment solutions and support further UK expansion.

Total raised

$48M

Funding rounds

2

Latest round

Series A

Latest activity

Feb 2026